Opening book details…
Can I read Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities on EtoBox?
Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities by John Hardy; Jonathan M. Schott is a Medicine article available to read on EtoBox.
What is Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities about?
In the last 2 years, there have been 3 successful trials of antiamyloid antibodies in Alzheimer disease (AD): aducanemab, now controversially US Food and Drug Administration-approved under the accelerated approval pathway 1 ; lecanemab, now FDA-approved 2 ; and donanemab, now going through the approval process. 3 All 3 share a common broad mechanism, that is, antibodymediated removal of β-amyloid (Aβ) from the brain, and this is almost certainly the basis of their therapeutic action. 4 When used in the earliest symptomatic stages of AD, all have modest clinical effects, all clear Aβ from the brain, and all show evidence for some changes in molecular markers believed to be downstream of Aβ accumulation in keeping with disease modification. 4 However, all these drugs-and several other antiamyloid immunotherapies that failed to show positive effects in clinical trials (e.g. bapineuzemab and gantenerumab) 5,6 -have the troubling adverse event of antibody-related imaging abnormalities (ARIA). ARIA can take the form of vasogenic edema or sulcal effusion (ARIA-E) or haemosiderin deposition due to hemorrhage (ARIA-H). 7 In vivo, ARIA is detected using MRI: ARIA-E is visible on fluid attenu
Who reads Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- John Hardy; Jonathan M. Schott
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Published
- 2024
- Language
- EN
- Field
- Medicine (Health Sciences)